Sientra Inc (NASDAQ:SIEN) Director Timothy Haines sold 89,651 shares of the firm’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the transaction, the director now directly owns 37,662 shares of the company’s stock, valued at $811,992.72. The sale was disclosed in a document filed with the SEC, which is available through this link.
Shares of NASDAQ SIEN opened at $18.62 on Friday. Sientra Inc has a 1 year low of $8.79 and a 1 year high of $26.79. The company has a market cap of $606.36 million, a P/E ratio of -6.60 and a beta of -0.37. The company has a current ratio of 3.06, a quick ratio of 2.63 and a debt-to-equity ratio of 0.27.
Sientra (NASDAQ:SIEN) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.05). Sientra had a negative return on equity of 162.07% and a negative net margin of 126.03%. The firm had revenue of $16.90 million for the quarter, compared to analyst estimates of $16.66 million. During the same quarter last year, the business posted ($0.74) EPS. The firm’s revenue was up 72.4% compared to the same quarter last year. Sell-side analysts anticipate that Sientra Inc will post -2.93 earnings per share for the current year.
A number of brokerages have recently weighed in on SIEN. Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Wednesday. BidaskClub cut shares of Sientra from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 18th. Dougherty & Co began coverage on shares of Sientra in a research note on Thursday, August 30th. They set a “buy” rating and a $31.00 price objective for the company. Finally, Stephens reissued a “buy” rating and set a $30.00 price objective on shares of Sientra in a research note on Thursday, August 9th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $22.50.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: What is a stock buyback?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.